Pediatric Blood & Cancer最新文献

{"title":"Correction to Assessment of Barrier and Enabler for Implementing a Population-Based Childhood Cancer Registry in Chennai, India","authors":"","doi":"10.1002/pbc.31652","DOIUrl":"10.1002/pbc.31652","url":null,"abstract":"<p>V. Radhakrishnan, A. Jothi, R. Mary, et al. Assessment of Barriers and Enablers for Implementing a Population-Based Childhood Cancer Registry in Chennai, India<i>. Pediatric Blood &amp; Cancer</i>.72, no. 3 (2024): e31500. \u0000https://doi.org/10.1002/pbc.31500.</p><p>The formatting of Table 3 has been corrected. The updated table is shown on the following page.</p><p>We apologize for this error.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 6","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.31652","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Childhood Cancer Early Diagnosis and Appropriate Referral: An Educational Initiative of the International Society of Paediatric Oncology (SIOP), in Collaboration With International Pediatric Association.","authors":"Muhammad Saghir Khan, Claudia Sampor, Mychelle Farmer, Neil Ranasinghe, Elizabeth Sniderman, Maya Prasad, Trisha Soosay Raj, Rashmi Dalvi, Joyce Balagadde Kambugu, Reineke A Schoot, Daniel C Moreira, Erin Christine Peckham-Gregory, Julia Challinor, Lorena Segovia Weber, Aman Pulungan, Guillermo Chantada, Susanne Wollaert, Anelia Atanasova, Rejin Kebudi, Enver Hasanoglu, Naveen Thacker, Kathy Pritchard-Jones","doi":"10.1002/pbc.31702","DOIUrl":"https://doi.org/10.1002/pbc.31702","url":null,"abstract":"<p><p>A long pre-diagnostic interval is reported to be a significant challenge in childhood cancer, particularly in low- and middle-income countries (LMICs) where advanced-stage disease at diagnosis results in poor survival. The International Society of Paediatric Oncology and the International Pediatric Association launched the \"Childhood Cancer Early Diagnosis and Appropriate Referral (CEDAR)\" project in 2022 as educational webinars on the six index childhood cancers of the World Health Organization Global Initiative for Childhood Cancer to improve awareness of healthcare providers (HCP). Pediatricians, family practitioners, and community nurses involved in diagnostic workups and patient referrals participated (n = 2737). Webinar attendance indicated strong HCP global engagement overall.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31702"},"PeriodicalIF":2.4,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular Safety and Visual Acuity Stability in Pediatric Patients With Optic Pathway Gliomas and Orbital Plexiform Neurofibromas Treated With BRAF and MEK Inhibitors.","authors":"Aviv Sever, Gad Dotan, Dafna Brik, Ariela Zaikin, Helen Toledano","doi":"10.1002/pbc.31709","DOIUrl":"https://doi.org/10.1002/pbc.31709","url":null,"abstract":"<p><strong>Background: </strong>BRAF and MEK inhibitors targeting the RAS/MAPK pathway are increasingly used in pediatric oncology, particularly for gliomas and neurofibromatosis type 1-associated plexiform neurofibromas (PN). While ocular adverse events (OAE), such as uveitis and MEK inhibitor-associated retinopathy (MEKAR), are well documented in adults, pediatric data remain limited, as are data regarding the effect on visual acuity (VA) in optic pathway gliomas (OPG) and orbital plexiform neurofibromas (OPN).</p><p><strong>Methods: </strong>This retrospective study reviewed pediatric patients treated with BRAF and/or MEK inhibitors (years 2015-2024). Ophthalmologic assessments, including VA and optical coherence tomography (OCT), were conducted at baseline and follow-up. Patients were categorized based on optic pathway involvement (OPG/OPN vs. non-OPG/OPN).</p><p><strong>Results: </strong>Among 62 patients (120 eyes), OAE occurred in 3 (4.8%): 1/29 in the OPG/OPN group and 2/33 in the non-OPG/OPN group. All were reversible with dose adjustment or discontinuation. In the OPG/OPN group, VA data were available for 35 eyes, with stability in 74% (26/35), improvement in 17% (6/35), and a decline in 9% (3/35). In the non-OPG/OPN group (57 eyes), VA remained stable in 91% (52/57). Optic disc appearance, retinal nerve fiber layer thickness, and macular thickness remained stable over a 22-month median follow-up in both groups.</p><p><strong>Conclusions: </strong>BRAF and MEK inhibitors demonstrate ocular safety in children, including those with OPG/OPN, with rare, reversible OAE and stable VA. These findings support their use in pediatric patients even with optic pathway involvement. Regular ophthalmologic monitoring with OCT and VA assessments remains essential for safe, long-term use.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31709"},"PeriodicalIF":2.4,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Larotrectinib Monotherapy After a Subtotal Resection of Infantile Hemispheric Glioma With TPM3::NTRK1 Fusion.","authors":"Satomi Yokoyama, Utako Oba, Toya Shunichiro, Yoshinao Oda, Koji Yoshimoto, Yasunari Sakai, Yuhki Koga, Shouichi Ohga","doi":"10.1002/pbc.31694","DOIUrl":"https://doi.org/10.1002/pbc.31694","url":null,"abstract":"","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31694"},"PeriodicalIF":2.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Portal Use Among Patients With Vascular Anomalies and Their Caregivers","authors":"Sunny C. Lin,&nbsp;Anna Kerr,&nbsp;Christine Bereitschaft,&nbsp;Bryan Sisk","doi":"10.1002/pbc.31706","DOIUrl":"10.1002/pbc.31706","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients with vascular anomalies (VAs) experience poor communication and have unmet information needs. Online patient portals could mitigate communication barriers and support communication interventions. However, these portals are often underutilized.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Procedure</h3>\u0000 \u0000 <p>We retrospectively queried audit-log data from the Electronic Health Record (EHR) of a single large academic healthcare center for all patients seen by clinicians from a multidisciplinary specialist clinic with a diagnosed VA from January 2020 to January 2024. We connected audit-log data with patient demographics to examine how patients used the portal, and whether use varied by patient characteristics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We queried portal usage for 315 patients with vascular anomalies, of whom 43% were children, 19% were adolescents, and 38% were adults. Approximately half of patients’ portals were logged into during the study period (51%, <i>n</i> = 162). Of users who ever logged into the portal, the median number of logins per year were 35 (interquartile range 15 to 95). Multiple regression results show that portal access was higher for patients who are White, reside in a metropolitan area, and have lower Area Deprivation Index. Of users who ever logged into the portal, 77% viewed clinician notes, 90% viewed test results, and 71% engaged in messaging with a clinician at least once.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Half of patients and caregivers never use the portal, and patients from less urban areas with higher deprivation are even less likely to use the portal. As portals become more integrated into patient care, these inequities in portal access could lead to inequities in health outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 6","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 2035 Clinical Research Vision and Roadmap for High-Risk Neuroblastoma","authors":"Lucas Moreno,&nbsp;Steven G. Dubois,&nbsp;Nicholas Bird,&nbsp;Leona Knox,&nbsp;Donna Ludwinski,&nbsp;Andrew D. J. Pearson,&nbsp;Maja Beck-Popovic,&nbsp;Rochelle Bagatell","doi":"10.1002/pbc.31660","DOIUrl":"10.1002/pbc.31660","url":null,"abstract":"<div>\u0000 \u0000 <p>Despite the introduction of anti-GD2 antibody therapy, outcomes for children with high-risk neuroblastoma remain poor, with low cure rates and a high proportion of survivors facing long-term sequelae. In this report, leaders from international cooperative groups and patient advocacy organizations review lessons learnt, identify current challenges, and provide a vision to bring new agents into frontline therapy to increase cure rates and reduce long-term toxicities over the next decade. The implementation of this vision requires improved global collaboration, incorporation of novel biomarkers, and a strengthened interaction with the regulatory landscape.</p>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 6","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid Enoxaparin Adjustment for Childhood Thrombosis/Thromboprophylaxis","authors":"Joel Livingston,&nbsp;Leanne Meakins,&nbsp;Aisha Bruce,&nbsp;David Stammers,&nbsp;Catherine Corriveau-Bourque,&nbsp;Anna Serebrin,&nbsp;Kerry Wong,&nbsp;Mary Bauman","doi":"10.1002/pbc.31691","DOIUrl":"10.1002/pbc.31691","url":null,"abstract":"<p>Enoxaparin dosing in children is imperfect and strategies to optimize initial therapy for patients at high-thrombotic risk would be of clinical benefit. This study looked at using peak-post-first-enoxaparin-dose anti-Xa to guide subsequent enoxaparin dose and timing of administration in children deemed high-thrombotic risk. Fourteen patients (seven aged &lt;3 months, seven children/adolescents) were identified and reviewed retrospectively. All patients were commenced on a therapeutic enoxaparin dose within ≤20 h with average time to therapeutic anti-Xa of 15.4 h (range 4–34 h) for neonates/infants and 10.8 h (range 4–24 h) for children/adolescents. No patient had supratherapeutic anti-Xa or thrombotic/bleeding events. Further studies are needed to validate this approach.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 6","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.31691","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uniting for Change: The GLOW Initiative and Its Impact on Nodular Lymphocyte-Predominant Hodgkin Lymphoma","authors":"Diana M. Fridlyand,&nbsp;Frank Keller","doi":"10.1002/pbc.31699","DOIUrl":"10.1002/pbc.31699","url":null,"abstract":"","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 6","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paraneoplastic Ichthyosis Preceding the Diagnosis of Gluteal Rhabdomyosarcoma at Initial Presentation and Relapse","authors":"Swetha Palla,&nbsp;Richa Jain,&nbsp;Sunil Dogra,&nbsp;Prema Menon,&nbsp;Uma Nahar,&nbsp;Deepak Bansal","doi":"10.1002/pbc.31703","DOIUrl":"10.1002/pbc.31703","url":null,"abstract":"","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 6","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Contemporary Surgical Management of Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcoma”","authors":"","doi":"10.1002/pbc.31719","DOIUrl":"10.1002/pbc.31719","url":null,"abstract":"<p>Polites SF, Rhee DS, Seitz G, et al. Contemporary Surgical Management of Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcoma. <i>Pediatr Blood Cancer</i>. 2024; 71:e31257. https://onlinelibrary.wiley.com/doi/10.1002/pbc.31257</p><p>The above-mentioned article for this Special Issue was mistakenly published in an earlier issue. The article's abstract is shown here:</p><p><b>ABSTRACT</b></p><p>Non-rhabdomyosarcoma soft tissue sarcoma (STS) comprises most STS in pediatric patients. It is a diverse set of over 30 histologic subtypes. Treatment is based on risk group determined by tumor size, grade, and the presence of metastases. Surgical resection is a cornerstone of therapy, as tumors are often resistant to chemotherapy or radiation. While patients with isolated tumors less than 5 cm may undergo upfront resection, strong consideration should be given to neoadjuvant chemoradiotherapy to ensure negative margins at surgical resection and optimal outcomes. Sentinel lymph node biopsy is strongly recommended for clear cell and epithelioid sarcomas. The most common metastatic site is the lung, and metastases should be resected at the end of therapy, when feasible. Unfortunately, many high-risk patients progress on therapy, and alternative strategies including earlier metastatic control require investigation.</p><p>We apologize for this error.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 S2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.31719","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}